Lorlatinib is a targeted therapy medication used in the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Specifically, Lorlatinib targets and inhibits the activities of anaplastic lymphoma kinase (ALK) and ROS1, which are proteins involved in the growth and spread of cancer cells.
